FDA approves Technivie for treatment of chronic hepatitis C genotype 4

The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis).
Source: Food and Drug Administration - Category: American Health Source Type: news

Related Links:

Authors: Nehra V, Rizza SA, Temesgen Z Abstract The fixed-dose combination of glecaprevir (GLE), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and pibrentasvir (PIB), an NS5A inhibitor, was recently approved for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1-6 (GT-1-6) without cirrhosis or with compensated cirrhosis, and for the treatment of HCV GT-1 patients who have failed treatment with either NS5A inhibitors or NS3/4A protease inhibitors, but not both. This combination, administered over 8 or 12 weeks, has resulted in high cure rates in all six HCV genotypes, includ...
Source: Drugs of Today - Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
Conclusion: We found a significant difference in DCV levels at 2 weeks and 1 month: 150 ng/mL in patients without MET and 313 ng/mL with MET at 2 weeks (p #x3c; 0.001), 149 and 279  ng/mL at 1 month (p = 0.006). DCV levels were lower in cirrhotic patients (p #x3c; 0.001); among cirrhotic patients we also evidenced higher DCV concentrations in patients receiving MET at 2 weeks, 1 and 2 months (p #x3c; 0.001,p = 0.005, andp = 0.031, respectively). In multivariate analysis, the only predictive factor associated with DCV plasma levels was the  presence of MET. The reason for this increased DCV exposure is unclear; on...
Source: European Addiction Research - Category: Addiction Source Type: research
AbstractObjectivesTo assess the efficacy and safety of sofosbuvir based generic Direct Acting Antivirals (DAAs) in treatment of Hepatitis C virus (HCV) in adolescents with thalassemia major (TM).MethodsIn this prospective single-arm study, 18 TM adolescents with Chronic Hepatitis C received sofosbuvir based generic DAAs. Patients with genotype 1 and genotype 3 received ledipasvir and daclatasvir respectively. Two cirrhotic patients with genotype 3 also received ribavirin.ResultsThe mean age of patients was 15.1 y, of which 12 had genotype 1, 5 had genotype 3 and 1 had an undetermined genotype. Six patients had cirrhosis an...
Source: Indian Journal of Pediatrics - Category: Pediatrics Source Type: research
ConclusionSVR among real-world HCV/HIV coinfected populations treated with DAA regimens is similar to SVR of patients studied in clinical trials. Historically negative predictors of achieving SVR during the era of interferon-based treatments, such as those with cirrhosis, prior HCV treatment failure, GT1 infection, and African-American race, are not associated with a significantly lower SVR in real-world populations treated with various DAA regimens.
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
Conditions:   Hepatitis C;   Hepatitis B;   Liver Cirrhoses Intervention:   Drug: PRI-724 Sponsors:   Komagome Hospital;   Prism Pharma Co., Ltd.;   Kyushu University;   National Center for Global Health and Medicine, Japan;   Japan Agency for Medical Research and Development Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Chronic hepatitis C virus infection (HCV) is a global health problem causing death and morbidity [1]. Recent studies have shown that the global prevalence of HCV is estimated to be 1% in 2015, corresponding to 71.1 million individuals with chronic HCV infection [2,3]. The disease burden of HCV infection is due to progression of chronic liver disease, which can lead to cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death. Globally, 27% of all cases of cirrhosis and 25% of all HCC is attributable to HCV infection [4].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
RESUMO Objetivo: identificar a incid ência das infecções relacionadas à assistência à saúde e seus fatores associados, durante o primeiro mês do pós-operatório de pacientes adultos submetidos ao transplante hepático em um hospital público de Fortaleza. Método: estudo retrospectivo, descritivo com abordagem quantitativa, r ealizado com 53 receptores de fígado no primeiro semestre do ano de 2015. Os dados foram coletados através dos prontuários, fichas ambulatoriais e de notificação de infecç&otil...
Source: Texto e Contexto - Enfermagem - Category: International Medicine & Public Health Source Type: research
Authors: Wasfy E, Elkassas G, Elnawasany S, Elkasrawy K, Abd-Elsalam S, Soliman S, Badawi R Abstract Background&Aims: Esophageal varices (EV) are a major complication of portal hypertension in cirrhotic patients. Screening is essential for all patients with cirrhosis. Performing non-invasive methods for screening is a cost-effective and time-saving measure. The aim of this work is to evaluate whether insulin resistance (IR) assessed by HOMA-IR score can predict the presence of EV or not. METHODS: This cross-sectional study was carried out on sixty Egyptian cirrhotic HCV patients divided into 3 groups: Group...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Treatment of hepatitis C (HCV) with direct-acting antiviral agents does not appear to increase the risk of hepatocellular carcinoma (HCC) in individuals with cirrhosis, researchers from France report.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
Optimal care for hepatitis virus –related hepatocellular carcinoma (HCC) would include eradication of tumor and elimination of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Accomplishing these goals could prevent deaths from cancer or cirrhosis and reduce the likelihood of viral transmission. Tremendous progress h as recently been achieved for tumor and antiviral therapies. Long-term survival from cancer was previously a rarity. Now, partial hepatectomy, liver transplant, or tumor ablation provide 5-year survival rates of 45% to 80%. Direct-acting antivirals (DAA) can now prevent cirrhosis in patients...
Source: JAMA Surgery - Category: Sports Medicine Source Type: research
More News: American Health | Cirrhosis | Food and Drug Administration (FDA) | Hepatitis | Hepatitis C | Liver | Norvir | Urology & Nephrology